Cost of latex labelling compliance not so high, says FDA
This article was originally published in Clinica
The FDA says its pending rule on natural rubber latex will not cost small medical device companies very much to implement. The 2,340 small device companies in the US will need to spend a total of $4.5 million to add the required information to their labelling on the latex content of the devices or their packaging, the agency said.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.